Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

87.68 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
Merck Announces Second-Quarter 2024 Financial Results
From Merck & Co., Inc.
Via Business Wire
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Smart Money Is Betting Big In MRK Options
Via Benzinga
Merck & Co Inc. DCF Valuation: Is The Stock Undervalued?
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. 
Via Talk Markets
Merck & Co's Options Frenzy: What You Need to Know
Via Benzinga
Evaluating Merck &amp; Co Against Peers In Pharmaceuticals Industry
Via Benzinga
Earnings Divide Dow Industrials As Crux Of Q2 Season Approaches
The Dow index declined 1.3% on Wednesday, undercutting short-term support. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
Merck shares topline results from its Phase 2b/3 trial of clesrovimab, showing efficacy in reducing RSV-related infections in infants. Clesrovimab met safety and efficacy endpoints. 
Via Benzinga
Merck Announces Fourth-Quarter 2024 Dividend
From Merck & Co., Inc.
Via Business Wire
Billionaires Are Loading Up on This Surging Dow Stock. Should You?
Merck stock has handily outperformed the Dow Jones Industrial Average in 2024, sparked by aggressive buying from billionaires like Citadel's Kenneth Griffin. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals. 
Via Chartmill
Merck's Acquisition of EyeBio Finalized
Merk announced the acquisition of EyeBio, introducing a novel candidate to the company's pipeline, Restoret. 
Via Benzinga
Beyond The Numbers: 6 Analysts Discuss Merck & Co Stock
Via Benzinga
Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
From Merck & Co., Inc.
Via Business Wire
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. 
Via The Motley Fool
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.
This fund has a basket of growth, income, and value stocks. 
Via The Motley Fool
Topics ETFs
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily
Merck Gets Legal Victory As Appeals Court Dismisses Shingles Vaccine Some 1,200 Lawsuits
Merck secures legal victory as 3rd U.S. Circuit Court of Appeals upholds dismissal of 1,200 lawsuits over Zostavax shingles vaccine. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
2 Magnificent Stocks to Buy With $500
These reliable healthcare companies look attractive no matter how you slice it. 
Via The Motley Fool
3 Top Cancer Treatment Stocks to Buy Now
These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term. 
Via InvestorPlace
3 Biotech Stocks to Buy in Case of Another Pandemic
These are three of the best biotech stocks to keep an eye on as the industry helps governments prepare for the next pandemic. 
Via InvestorPlace
Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024
From Merck & Co., Inc.
Via Business Wire
Forget Nvidia: Billionaires Are Dumping It and Piling Into These 3 Surprising Value Stocks Instead
Nvidia's three most-prominent billionaire sellers opted to put their respective fund's capital to work in a trio of brand-name companies trading at a discount. 
Via The Motley Fool
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck cancer... 
Via Benzinga
Merck Completes Acquisition of EyeBio
From Merck & Co., Inc.
Via Business Wire
3 Under-$10 Biotech Stocks That Could Make You Rich
Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis. 
Via InvestorPlace
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.